Avanos Medical (NYSE:AVNS) Announces Quarterly Earnings Results

Avanos Medical (NYSE:AVNS) released its quarterly earnings data on Tuesday. The company reported $0.28 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.25 by $0.03, Briefing.com reports. Avanos Medical had a net margin of 2.58% and a return on equity of 4.92%. The business had revenue of $172.20 million during the quarter, compared to analyst estimates of $172.02 million. During the same quarter last year, the business earned $0.20 earnings per share. Avanos Medical’s quarterly revenue was up 7.0% compared to the same quarter last year. Avanos Medical updated its FY 2019 guidance to $1.15-1.25 EPS and its FY19 guidance to $1.15-1.25 EPS.

Shares of Avanos Medical stock traded down $0.46 during trading on Tuesday, hitting $37.46. The stock had a trading volume of 15,961 shares, compared to its average volume of 263,067. The company has a fifty day simple moving average of $42.15. The firm has a market capitalization of $1.82 billion, a PE ratio of 45.74 and a beta of 1.46. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.22 and a current ratio of 2.77. Avanos Medical has a 12 month low of $37.07 and a 12 month high of $72.96.

In other news, CEO Joseph Fralin Woody bought 3,500 shares of the stock in a transaction dated Thursday, May 30th. The stock was purchased at an average price of $39.95 per share, for a total transaction of $139,825.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.57% of the stock is currently owned by company insiders.

Several equities analysts have commented on AVNS shares. ValuEngine upgraded shares of Avanos Medical from a “hold” rating to a “buy” rating in a research report on Tuesday, July 2nd. Morgan Stanley set a $47.00 price objective on shares of Avanos Medical and gave the company a “sell” rating in a research report on Wednesday, May 8th. Finally, Zacks Investment Research lowered shares of Avanos Medical from a “hold” rating to a “sell” rating in a research report on Monday, May 6th. Three investment analysts have rated the stock with a sell rating and three have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $63.00.

About Avanos Medical

Avanos Medical, Inc operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life worldwide. It provides a portfolio of products focuses on respiratory and digestive health; pain management solutions; and minimally invasive interventional pain therapies, closed airway suction systems, and enteral feeding tubes.

Further Reading: What is a growth and income fund?

Earnings History for Avanos Medical (NYSE:AVNS)

Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.